ANTX
AN2 Therapeutics, Inc.Company with tickers: ANTX
CIK
1880438
CUSIP
037326105
Shares Outstanding
36,016,161
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $10,551,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | $6,743,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Operating Income | $-10,551,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-10,028,000 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.29 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.29 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |